BCAX Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 7.09%, SMA50 1.51%, SMA200 19.51%). The stock’s 14-day RSI is 56.1 (neutral), while the ATR of 1.09 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -14.76% below its high and over 115.38% above its low. Average 10-day trading volume of 493.06 thousand shares is below the 3-month average of 718.49 thousand, indicating normal recent market interest.

Bicara Therapeutics Inc. Common Stock has 66.17 million shares outstanding. The public float is 36.90 million shares, elevated short interest at 20.40% of float. This equals 9.60 million shares. The short ratio is 15.33 days. Institutional investors hold 117.26% of the float. Insiders own 10.14%. RA CAPITAL MANAGEMENT, L.P. holds 2.20 million shares, Mazumdar Claire has 362.15 thousand shares and Cohlhepp Ryan has 181.64 thousand shares. Over the past six months, insider transactions show net selling. They sold 126.74 thousand shares across 20 transactions.

Bicara Therapeutics Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.74. This means the shares are trading above this model’s fair value.

Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX) closed at $22.81 USD, losing -$0.29 (-1.26%) from the previous close of $23.10. The stock is currently mid-range between its 52-week high and low $10.29 and $30.99. With a market capitalization of about $1.50 billion, Bicara Therapeutics Inc. Common Stock is classified as a small-cap and shows lower-than-market volatility (beta ~-0.82). Key stats such as the average daily volume over the past year has been around 727.91 thousand shares, volume is running light vs its 52-week average. Headquartered in Boston, MA, Bicara Therapeutics Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Claire Mazumdar Clemon, the company employs approximately 103 people and listed since September 13, 2024. Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts.

Wall Street analysts project EPS growth of 8.12% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 4 Buy ratings, 5 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $42.00 to $11.00. The high target offers 84.13% upside. The low target suggests -51.78% downside. The mean target is $28.00. This offers 22.75% upside. Bicara Therapeutics Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended August 11, 2026, missed forecasts by 0.03%. The prior quarter beat by 45.31%. Over the last six quarters, Apple has recorded several small beats. These include 70.0% in May 13, 2025.

Bicara Therapeutics Inc. Common Stock trades at a P/E ratio of -7.42, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.33 trading at moderately above to book value. The P/FCF stands at -11.18, also below market averages.

Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX) shares are flat -0.65% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Bicara Therapeutics Inc. Common Stock trading at a premium to the broader market with a P/E of -7.42. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $30.46, suggesting 33.54% upside. Our AI forecast model points to short-term weakness (-5.09% over two weeks), a medium-term rise (66.24% over three months), and a longer-term gain (30.12% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Bicara Therapeutics Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.09%, with price expected at $21.65 by September 25, 2026, within a range of $20.51 to $22.78 3-Month Outlook: Projected rise of 66.24%, reaching $37.92 by December 09, 2026, with a range of $37.41 to $38.45. 1-Year Outlook: Projected gain of 30.12%, with price at $29.68 by September 10, 2027, within a range of $28.05 to $31.71.